Quan Zheng

The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study

Abstract Introduction Surgical resection is the standard for early-stage lung adenocarcinoma (LUAD), but recurrence remains a risk for patients with epidermal growth factor receptor (EGFR) mutations. The efficacy of adjuvant EGFR tyrosine kinase inhibitors (EGFR-TKIs) in stage IA...